Christine Bader’s new book – “The Evolution of a Corporate Idealist: When Girl Meets Oil” – chronicles her work for oil giant BP, managing the community impacts of big projects in the developing world, and her later role as an advisor to a United Nations initiative on human rights abuses linked to business. Her hope, she says in an interview, is that someday corporate idealism “doesn’t seem like the oxymoron that it does to so many people today.”Full Story»
“We live not just in a global economy but in a global supply chain,” says international labor expert Richard Locke. “The most important thing is to educate consumers, especially in large markets, so they understand that the choices they make have implications for issues of living standards, working conditions and justice in the factories that produce most of the things we buy every day.”
In a major departure from industry practice, GlaxoSmithKline, the sixth-largest global drug maker, announced that it will no longer hire doctors to promote its drugs. The company also will stop tying compensation for sales representatives to the number of prescriptions written for drugs they market. The changes will be made worldwide over the next two years.
With greater gender diversity on a corporate board, comes better performance. Opinions differ as to why, but myriad research studies from leading academic institutions and the private sector all make a compelling case for more balanced gender representation on boards. The debate should be long over, yet women’s presence on U.S. corporate boards remains frustratingly, persistently low.
More in this category
- The Public Costs of Low Wages Paid by the Fast-Food Industry
- The Impact and Echoes of the Wal-Mart Discrimination Case
- Lessons Learned from the Financial Crisis
- Delaware Public Benefit Corporations Bring Social Purpose
- Sustainability Reporting Group Issues First Standards for SEC Filings
- Richard Branson and ‘The B Team’ Plan for Corporate Responsibility